Stomach Cancer Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Treatment Type (Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy, Others), By Cancer Type (Gastric Cancer/Gastroesophageal Junction Cancer v/s Gastrointestinal Stromal Tumors), By Route of Administration (Oral v/s Injectables), By Drug Class (PD-1/PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists, Others), By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Others), By Region and Competition
The global stomach cancer treatment market is anticipated to witness impressive growth during the forecast period. This can be ascribed to the growing development of novel drugs and therapies for treating stomach cancer. Additionally, growing demand for painless low-cost treatment and favorable reimbursement scenarios for the treatment of cancer have significantly increased the growth of stomach cancer treatment across different parts of the globe. Additionally, the growing aging population across the globe, which is more prone to different kinds of chronic diseases like stomach cancer, is further expected to increase the demand for different cancer therapies, thereby fuelling market growth through 2028. Besides, growing awareness about the benefits of new therapies, with increasing expenditure on cancer diseases worldwide, is further expected to support the stomach cancer treatment market during the forecast period.
Growing Prevalence of Stomach Cancer
Increasing incidences of adenocarcinoma, lymphoma, and gastrointestinal stromal tumors across the world are driving market growth during the forecast period. Similarly, the rising aging population is susceptible to chronic diseases like stomach cancer, which is one of the most common deadly cancers worldwide, especially among older males. This is expected to boost market growth in the forecast period. According to National Cancer Institute, in 2022, 26,380 new stomach cancer cases and 11,090 deaths are estimated in the United States. In developing countries, stomach cancer is more diagnosed in males than females because females carry an extra copy of certain protective genes in their cells that men don't have. The increasing prevalence of gastric cancer in the region is demanding effective therapies for treating patients, which, in turn, is expected to propel the market growth during the forecast period. For instance, according to the 2021 statistics published by the Canadian Cancer Society, 4,000 Canadians were affected by gastric cancer.
Growing Development In Healthcare Industry
Increasing approval of newly developed drugs from the government, along with the growing prevalence of stomach cancer, is expected to create a lucrative growth prospect for the stomach cancer market over the years. Research & Development activities play a major role in developing novel drugs and therapies. For instance, a research team from Taiwan has recently launched two gastric cancer biomarkers. This advancement may bring remarkable growth prospects for the stomach cancer market, thereby boosting the market growth. Similarly, oral drugs are expected to boost market growth during the forecast period as most products are available in capsules and tablets, making it a very feasible route of administration. Growing health awareness among the population is expected to boost the stomach cancer treatment market growth. The innovative therapy launches for treating gastric cancer are expected to enhance the market simultaneously. Different researchers and government organizations are investing in the development of novel drugs that benefit the market as well as the patient; this creates more opportunities in the market. It is estimated that 11,090 deaths (6,690 men and 4,400 women) from this disease will occur in the United States in 2022. In 2020, an estimated 768,793 people died from stomach cancer worldwide.
Market Segmentation
The global stomach cancer treatment market can be segmented by treatment type, cancer type, route of administration, drug class, distribution channel, and by region. Based on treatment type, the market can be segmented into Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy, and Others. Based on cancer type, the market can be differentiated into Gastric Cancer/Gastroesophageal Junction Cancer v/s Gastrointestinal Stromal Tumors. Based on the route of administration, the market can be divided into Oral v/s Injectables. Based on drug class, the market can be segmented into PD-1/PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists, and Others. Based on distribution channels, the market can be grouped into Hospital Pharmacies, Specialty Pharmacies, and Others. Regionally, North America dominated the market among Asia Pacific, Europe, Middle East & Africa, and South America. Among the different countries, the United States dominated the global stomach cancer treatment market on account of the growing demand for advanced cancer therapy in the country.
Market Players
Pfizer, Inc., Novartis International AG, Eli Lilly and Company, Bristol Myers Squibb Company, Teva Pharmaceutical Industries AG, F. Hoffmann La Roche AG, Mylan N.V., Celltrion Healthcare Co., Ltd, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd. are some of the leading players operating in the Global Stomach Cancer Treatment Market.
Recent Development
For instance, in April 2021, the U.S. FDA approved Bristol-Myers Squibb Company’s product Opdivo in combination with fluoropyrimidine- and platinum-containing chemotherapy for the treatment of metastatic gastric cancer.
Report Scope:
In this report, global stomach cancer treatment market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in Global Stomach Cancer Treatment Market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
Growing Prevalence of Stomach Cancer
Increasing incidences of adenocarcinoma, lymphoma, and gastrointestinal stromal tumors across the world are driving market growth during the forecast period. Similarly, the rising aging population is susceptible to chronic diseases like stomach cancer, which is one of the most common deadly cancers worldwide, especially among older males. This is expected to boost market growth in the forecast period. According to National Cancer Institute, in 2022, 26,380 new stomach cancer cases and 11,090 deaths are estimated in the United States. In developing countries, stomach cancer is more diagnosed in males than females because females carry an extra copy of certain protective genes in their cells that men don't have. The increasing prevalence of gastric cancer in the region is demanding effective therapies for treating patients, which, in turn, is expected to propel the market growth during the forecast period. For instance, according to the 2021 statistics published by the Canadian Cancer Society, 4,000 Canadians were affected by gastric cancer.
Growing Development In Healthcare Industry
Increasing approval of newly developed drugs from the government, along with the growing prevalence of stomach cancer, is expected to create a lucrative growth prospect for the stomach cancer market over the years. Research & Development activities play a major role in developing novel drugs and therapies. For instance, a research team from Taiwan has recently launched two gastric cancer biomarkers. This advancement may bring remarkable growth prospects for the stomach cancer market, thereby boosting the market growth. Similarly, oral drugs are expected to boost market growth during the forecast period as most products are available in capsules and tablets, making it a very feasible route of administration. Growing health awareness among the population is expected to boost the stomach cancer treatment market growth. The innovative therapy launches for treating gastric cancer are expected to enhance the market simultaneously. Different researchers and government organizations are investing in the development of novel drugs that benefit the market as well as the patient; this creates more opportunities in the market. It is estimated that 11,090 deaths (6,690 men and 4,400 women) from this disease will occur in the United States in 2022. In 2020, an estimated 768,793 people died from stomach cancer worldwide.
Market Segmentation
The global stomach cancer treatment market can be segmented by treatment type, cancer type, route of administration, drug class, distribution channel, and by region. Based on treatment type, the market can be segmented into Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy, and Others. Based on cancer type, the market can be differentiated into Gastric Cancer/Gastroesophageal Junction Cancer v/s Gastrointestinal Stromal Tumors. Based on the route of administration, the market can be divided into Oral v/s Injectables. Based on drug class, the market can be segmented into PD-1/PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists, and Others. Based on distribution channels, the market can be grouped into Hospital Pharmacies, Specialty Pharmacies, and Others. Regionally, North America dominated the market among Asia Pacific, Europe, Middle East & Africa, and South America. Among the different countries, the United States dominated the global stomach cancer treatment market on account of the growing demand for advanced cancer therapy in the country.
Market Players
Pfizer, Inc., Novartis International AG, Eli Lilly and Company, Bristol Myers Squibb Company, Teva Pharmaceutical Industries AG, F. Hoffmann La Roche AG, Mylan N.V., Celltrion Healthcare Co., Ltd, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd. are some of the leading players operating in the Global Stomach Cancer Treatment Market.
Recent Development
For instance, in April 2021, the U.S. FDA approved Bristol-Myers Squibb Company’s product Opdivo in combination with fluoropyrimidine- and platinum-containing chemotherapy for the treatment of metastatic gastric cancer.
Report Scope:
In this report, global stomach cancer treatment market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:
- Stomach Cancer Treatment Market, By Treatment Type:
- Immunotherapy
- Targeted Therapy
- Chemotherapy
- Radiation Therapy
- Others
- Stomach Cancer Treatment Market, By Cancer Type:
- Gastric Cancer/Gastroesophageal Junction Cancer
- Gastrointestinal Stromal Tumors
- Stomach Cancer Treatment Market, By Route of Administration:
- Oral
- Injectables
- Stomach Cancer Treatment Market, By Drug Class:
- PD-1/PD-L1 Inhibitors
- HER2 Antagonists
- VEGFR2 Antagonists
- Others
- Stomach Cancer Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Specialty Pharmacies
- Others
- Stomach Cancer Treatment Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- Germany
- United Kingdom
- Italy
- Spain
- Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Turkey
- Egypt
Company Profiles: Detailed analysis of the major companies present in Global Stomach Cancer Treatment Market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL STOMACH CANCER TREATMENT MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Treatment Type (Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy, Others)
5.2.2. By Cancer Type (Gastric Cancer/Gastroesophageal Junction Cancer v/s Gastrointestinal Stromal Tumors)
5.2.3. By Route of Administration (Oral v/s Injectables)
5.2.4. By Drug Class (PD-1/PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists, Others)
5.2.5. By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Others)
5.2.6. By Region
5.2.7. By Company (2022)
5.3. Market Map
5.3.1. By Treatment Type
5.3.2. By Cancer Type
5.3.3. By Route of Administration
5.3.4. By Drug Class
5.3.5. By Distribution Channel
5.3.6. By Region
6. NORTH AMERICA STOMACH CANCER TREATMENT MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Treatment Type
6.2.2. By Cancer Type
6.2.3. By Route of Administration
6.2.4. By Drug Class
6.2.5. By Distribution Channel
6.2.6. By Country
6.3. North America: Country Analysis
6.3.1. United States Stomach Cancer Treatment Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Treatment Type
6.3.1.2.2. By Cancer Type
6.3.1.2.3. By Route of Administration
6.3.1.2.4. By Drug Class
6.3.1.2.5. By Distribution Channel
6.3.2. Canada Stomach Cancer Treatment Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Treatment Type
6.3.2.2.2. By Cancer Type
6.3.2.2.3. By Route of Administration
6.3.2.2.4. By Drug Class
6.3.2.2.5. By Distribution Channel
6.3.3. Mexico Stomach Cancer Treatment Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Treatment Type
6.3.3.2.2. By Cancer Type
6.3.3.2.3. By Route of Administration
6.3.3.2.4. By Drug Class
6.3.3.2.5. By Distribution Channel
7. EUROPE STOMACH CANCER TREATMENT MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Treatment Type
7.2.2. By Cancer Type
7.2.3. By Route of Administration
7.2.4. By Drug Class
7.2.5. By Distribution Channel
7.2.6. By Country
7.3. Europe: Country Analysis
7.3.1. France Stomach Cancer Treatment Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Treatment Type
7.3.1.2.2. By Cancer Type
7.3.1.2.3. By Route of Administration
7.3.1.2.4. By Drug Class
7.3.1.2.5. By Distribution Channel
7.3.2. Germany Stomach Cancer Treatment Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Treatment Type
7.3.2.2.2. By Cancer Type
7.3.2.2.3. By Route of Administration
7.3.2.2.4. By Drug Class
7.3.2.2.5. By Distribution Channel
7.3.3. United Kingdom Stomach Cancer Treatment Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Treatment Type
7.3.3.2.2. By Cancer Type
7.3.3.2.3. By Route of Administration
7.3.3.2.4. By Drug Class
7.3.3.2.5. By Distribution Channel
7.3.4. Italy Stomach Cancer Treatment Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Treatment Type
7.3.4.2.2. By Cancer Type
7.3.4.2.3. By Route of Administration
7.3.4.2.4. By Drug Class
7.3.4.2.5. By Distribution Channel
7.3.5. Spain Stomach Cancer Treatment Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Treatment Type
7.3.5.2.2. By Cancer Type
7.3.5.2.3. By Route of Administration
7.3.5.2.4. By Drug Class
7.3.5.2.5. By Distribution Channel
8. ASIA-PACIFIC STOMACH CANCER TREATMENT MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Treatment Type
8.2.2. By Cancer Type
8.2.3. By Route of Administration
8.2.4. By Drug Class
8.2.5. By Distribution Channel
8.2.6. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Stomach Cancer Treatment Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Treatment Type
8.3.1.2.2. By Cancer Type
8.3.1.2.3. By Route of Administration
8.3.1.2.4. By Drug Class
8.3.1.2.5. By Distribution Channel
8.3.2. India Stomach Cancer Treatment Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Treatment Type
8.3.2.2.2. By Cancer Type
8.3.2.2.3. By Route of Administration
8.3.2.2.4. By Drug Class
8.3.2.2.5. By Distribution Channel
8.3.3. Japan Stomach Cancer Treatment Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Treatment Type
8.3.3.2.2. By Cancer Type
8.3.3.2.3. By Route of Administration
8.3.3.2.4. By Drug Class
8.3.3.2.5. By Distribution Channel
8.3.4. South Korea Stomach Cancer Treatment Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Treatment Type
8.3.4.2.2. By Cancer Type
8.3.4.2.3. By Route of Administration
8.3.4.2.4. By Drug Class
8.3.4.2.5. By Distribution Channel
8.3.5. Australia Stomach Cancer Treatment Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Treatment Type
8.3.5.2.2. By Cancer Type
8.3.5.2.3. By Route of Administration
8.3.5.2.4. By Drug Class
8.3.5.2.5. By Distribution Channel
9. SOUTH AMERICA STOMACH CANCER TREATMENT MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Treatment Type
9.2.2. By Cancer Type
9.2.3. By Route of Administration
9.2.4. By Drug Class
9.2.5. By Distribution Channel
9.2.6. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Stomach Cancer Treatment Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Treatment Type
9.3.1.2.2. By Cancer Type
9.3.1.2.3. By Route of Administration
9.3.1.2.4. By Drug Class
9.3.1.2.5. By Distribution Channel
9.3.2. Argentina Stomach Cancer Treatment Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Treatment Type
9.3.2.2.2. By Cancer Type
9.3.2.2.3. By Route of Administration
9.3.2.2.4. By Drug Class
9.3.2.2.5. By Distribution Channel
9.3.3. Colombia Stomach Cancer Treatment Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Treatment Type
9.3.3.2.2. By Cancer Type
9.3.3.2.3. By Route of Administration
9.3.3.2.4. By Drug Class
9.3.3.2.5. By Distribution Channel
10. MIDDLE EAST AND AFRICA STOMACH CANCER TREATMENT MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Treatment Type
10.2.2. By Cancer Type
10.2.3. By Route of Administration
10.2.4. By Drug Class
10.2.5. By Distribution Channel
10.2.6. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Stomach Cancer Treatment Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Treatment Type
10.3.1.2.2. By Cancer Type
10.3.1.2.3. By Route of Administration
10.3.1.2.4. By Drug Class
10.3.1.2.5. By Distribution Channel
10.3.2. Saudi Arabia Stomach Cancer Treatment Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Treatment Type
10.3.2.2.2. By Cancer Type
10.3.2.2.3. By Route of Administration
10.3.2.2.4. By Drug Class
10.3.2.2.5. By Distribution Channel
10.3.3. UAE Stomach Cancer Treatment Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Treatment Type
10.3.3.2.2. By Cancer Type
10.3.3.2.3. By Route of Administration
10.3.3.2.4. By Drug Class
10.3.3.2.5. By Distribution Channel
10.3.4. Turkey Stomach Cancer Treatment Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1. By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1. By Treatment Type
10.3.4.2.2. By Cancer Type
10.3.4.2.3. By Route of Administration
10.3.4.2.4. By Drug Class
10.3.4.2.5. By Distribution Channel
10.3.5. Egypt Stomach Cancer Treatment Market Outlook
10.3.5.1. Market Size & Forecast
10.3.5.1.1. By Value
10.3.5.2. Market Share & Forecast
10.3.5.2.1. By Treatment Type
10.3.5.2.2. By Cancer Type
10.3.5.2.3. By Route of Administration
10.3.5.2.4. By Drug Class
10.3.5.2.5. By Distribution Channel
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Recent Developments
12.2. Mergers & Acquisitions
12.3. Product Launches
13. COMPETITIVE LANDSCAPE
13.1. Business Overview
13.2. Product Offerings
13.3. Recent Developments
13.4. Financials (As Reported)
13.5. Key Personnel
13.6. SWOT Analysis
13.6.1. Pfizer, Inc.
13.6.2. Novartis International AG
13.6.3. Eli Lilly and Company
13.6.4. Bristol Myers Squibb Company
13.6.5. Teva Pharmaceutical Industries AG
13.6.6. F. Hoffmann La Roche AG
13.6.7. Mylan N.V.
13.6.8. Celltrion Healthcare Co., Ltd
13.6.9. Merck & Co., Inc.
13.6.10. Teva Pharmaceutical Industries Ltd.
14. STRATEGIC RECOMMENDATIONS
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL STOMACH CANCER TREATMENT MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Treatment Type (Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy, Others)
5.2.2. By Cancer Type (Gastric Cancer/Gastroesophageal Junction Cancer v/s Gastrointestinal Stromal Tumors)
5.2.3. By Route of Administration (Oral v/s Injectables)
5.2.4. By Drug Class (PD-1/PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists, Others)
5.2.5. By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Others)
5.2.6. By Region
5.2.7. By Company (2022)
5.3. Market Map
5.3.1. By Treatment Type
5.3.2. By Cancer Type
5.3.3. By Route of Administration
5.3.4. By Drug Class
5.3.5. By Distribution Channel
5.3.6. By Region
6. NORTH AMERICA STOMACH CANCER TREATMENT MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Treatment Type
6.2.2. By Cancer Type
6.2.3. By Route of Administration
6.2.4. By Drug Class
6.2.5. By Distribution Channel
6.2.6. By Country
6.3. North America: Country Analysis
6.3.1. United States Stomach Cancer Treatment Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Treatment Type
6.3.1.2.2. By Cancer Type
6.3.1.2.3. By Route of Administration
6.3.1.2.4. By Drug Class
6.3.1.2.5. By Distribution Channel
6.3.2. Canada Stomach Cancer Treatment Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Treatment Type
6.3.2.2.2. By Cancer Type
6.3.2.2.3. By Route of Administration
6.3.2.2.4. By Drug Class
6.3.2.2.5. By Distribution Channel
6.3.3. Mexico Stomach Cancer Treatment Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Treatment Type
6.3.3.2.2. By Cancer Type
6.3.3.2.3. By Route of Administration
6.3.3.2.4. By Drug Class
6.3.3.2.5. By Distribution Channel
7. EUROPE STOMACH CANCER TREATMENT MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Treatment Type
7.2.2. By Cancer Type
7.2.3. By Route of Administration
7.2.4. By Drug Class
7.2.5. By Distribution Channel
7.2.6. By Country
7.3. Europe: Country Analysis
7.3.1. France Stomach Cancer Treatment Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Treatment Type
7.3.1.2.2. By Cancer Type
7.3.1.2.3. By Route of Administration
7.3.1.2.4. By Drug Class
7.3.1.2.5. By Distribution Channel
7.3.2. Germany Stomach Cancer Treatment Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Treatment Type
7.3.2.2.2. By Cancer Type
7.3.2.2.3. By Route of Administration
7.3.2.2.4. By Drug Class
7.3.2.2.5. By Distribution Channel
7.3.3. United Kingdom Stomach Cancer Treatment Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Treatment Type
7.3.3.2.2. By Cancer Type
7.3.3.2.3. By Route of Administration
7.3.3.2.4. By Drug Class
7.3.3.2.5. By Distribution Channel
7.3.4. Italy Stomach Cancer Treatment Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Treatment Type
7.3.4.2.2. By Cancer Type
7.3.4.2.3. By Route of Administration
7.3.4.2.4. By Drug Class
7.3.4.2.5. By Distribution Channel
7.3.5. Spain Stomach Cancer Treatment Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Treatment Type
7.3.5.2.2. By Cancer Type
7.3.5.2.3. By Route of Administration
7.3.5.2.4. By Drug Class
7.3.5.2.5. By Distribution Channel
8. ASIA-PACIFIC STOMACH CANCER TREATMENT MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Treatment Type
8.2.2. By Cancer Type
8.2.3. By Route of Administration
8.2.4. By Drug Class
8.2.5. By Distribution Channel
8.2.6. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Stomach Cancer Treatment Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Treatment Type
8.3.1.2.2. By Cancer Type
8.3.1.2.3. By Route of Administration
8.3.1.2.4. By Drug Class
8.3.1.2.5. By Distribution Channel
8.3.2. India Stomach Cancer Treatment Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Treatment Type
8.3.2.2.2. By Cancer Type
8.3.2.2.3. By Route of Administration
8.3.2.2.4. By Drug Class
8.3.2.2.5. By Distribution Channel
8.3.3. Japan Stomach Cancer Treatment Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Treatment Type
8.3.3.2.2. By Cancer Type
8.3.3.2.3. By Route of Administration
8.3.3.2.4. By Drug Class
8.3.3.2.5. By Distribution Channel
8.3.4. South Korea Stomach Cancer Treatment Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Treatment Type
8.3.4.2.2. By Cancer Type
8.3.4.2.3. By Route of Administration
8.3.4.2.4. By Drug Class
8.3.4.2.5. By Distribution Channel
8.3.5. Australia Stomach Cancer Treatment Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Treatment Type
8.3.5.2.2. By Cancer Type
8.3.5.2.3. By Route of Administration
8.3.5.2.4. By Drug Class
8.3.5.2.5. By Distribution Channel
9. SOUTH AMERICA STOMACH CANCER TREATMENT MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Treatment Type
9.2.2. By Cancer Type
9.2.3. By Route of Administration
9.2.4. By Drug Class
9.2.5. By Distribution Channel
9.2.6. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Stomach Cancer Treatment Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Treatment Type
9.3.1.2.2. By Cancer Type
9.3.1.2.3. By Route of Administration
9.3.1.2.4. By Drug Class
9.3.1.2.5. By Distribution Channel
9.3.2. Argentina Stomach Cancer Treatment Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Treatment Type
9.3.2.2.2. By Cancer Type
9.3.2.2.3. By Route of Administration
9.3.2.2.4. By Drug Class
9.3.2.2.5. By Distribution Channel
9.3.3. Colombia Stomach Cancer Treatment Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Treatment Type
9.3.3.2.2. By Cancer Type
9.3.3.2.3. By Route of Administration
9.3.3.2.4. By Drug Class
9.3.3.2.5. By Distribution Channel
10. MIDDLE EAST AND AFRICA STOMACH CANCER TREATMENT MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Treatment Type
10.2.2. By Cancer Type
10.2.3. By Route of Administration
10.2.4. By Drug Class
10.2.5. By Distribution Channel
10.2.6. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Stomach Cancer Treatment Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Treatment Type
10.3.1.2.2. By Cancer Type
10.3.1.2.3. By Route of Administration
10.3.1.2.4. By Drug Class
10.3.1.2.5. By Distribution Channel
10.3.2. Saudi Arabia Stomach Cancer Treatment Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Treatment Type
10.3.2.2.2. By Cancer Type
10.3.2.2.3. By Route of Administration
10.3.2.2.4. By Drug Class
10.3.2.2.5. By Distribution Channel
10.3.3. UAE Stomach Cancer Treatment Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Treatment Type
10.3.3.2.2. By Cancer Type
10.3.3.2.3. By Route of Administration
10.3.3.2.4. By Drug Class
10.3.3.2.5. By Distribution Channel
10.3.4. Turkey Stomach Cancer Treatment Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1. By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1. By Treatment Type
10.3.4.2.2. By Cancer Type
10.3.4.2.3. By Route of Administration
10.3.4.2.4. By Drug Class
10.3.4.2.5. By Distribution Channel
10.3.5. Egypt Stomach Cancer Treatment Market Outlook
10.3.5.1. Market Size & Forecast
10.3.5.1.1. By Value
10.3.5.2. Market Share & Forecast
10.3.5.2.1. By Treatment Type
10.3.5.2.2. By Cancer Type
10.3.5.2.3. By Route of Administration
10.3.5.2.4. By Drug Class
10.3.5.2.5. By Distribution Channel
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Recent Developments
12.2. Mergers & Acquisitions
12.3. Product Launches
13. COMPETITIVE LANDSCAPE
13.1. Business Overview
13.2. Product Offerings
13.3. Recent Developments
13.4. Financials (As Reported)
13.5. Key Personnel
13.6. SWOT Analysis
13.6.1. Pfizer, Inc.
13.6.2. Novartis International AG
13.6.3. Eli Lilly and Company
13.6.4. Bristol Myers Squibb Company
13.6.5. Teva Pharmaceutical Industries AG
13.6.6. F. Hoffmann La Roche AG
13.6.7. Mylan N.V.
13.6.8. Celltrion Healthcare Co., Ltd
13.6.9. Merck & Co., Inc.
13.6.10. Teva Pharmaceutical Industries Ltd.
14. STRATEGIC RECOMMENDATIONS
